Insilico Medicine agreed to a transaction that will split global rights for a brain‑penetrant NLRP3 inhibitor, generating roughly $66 million in total deal value and an upfront payment in the low‑double‑digit millions, the company said. The arrangement allocates development and commercialization rights between Insilico and a Chinese partner and reflects growing interest in NLRP3 as a target for neuroinflammation and neurodegenerative diseases. Separately, Fosun‑funded Hygtia Therapeutics licensed the same Insilico‑discovered NLRP3 asset for Parkinson’s disease development in China and other territories, with a deal structure that grants Hygtia half the global rights and milestone economics. Hygtia will advance preclinical work and assume development in specified regions while Insilico retains co‑development option rights elsewhere. The deals underscore a continuing trend: AI‑driven discovery companies monetizing preclinical assets through regional licensing and co‑development partnerships to accelerate clinical translation while sharing commercial risk. NLRP3 inhibitors target innate immune inflammasome signaling implicated in neurodegeneration; the space has attracted multiple players and strategic interest.